Atara Biotherapeutics Inc (NASDAQ: ATRA) stock jumped 9.41% on Monday to $0.56 against a previous-day closing price of $0.51. With 8.11 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.43 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.5800 whereas the lowest price it dropped to was $0.5115. The 52-week range on ATRA shows that it touched its highest point at $5.64 and its lowest point at $0.20 during that stretch. It currently has a 1-year price target of $8.12. Beta for the stock currently stands at 0.72.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATRA was up-trending over the past week, with a rise of 117.04%, but this was down by -59.27% over a month. Three-month performance dropped to -61.78% while six-month performance fell -73.43%. The stock lost -87.05% in the past year, while it has lost -82.99% so far this year. A look at the trailing 12-month EPS for ATRA yields -2.77 with Next year EPS estimates of -1.27. For the next quarter, that number is -0.51. This implies an EPS growth rate of -10.80% for this year and 48.72% for next year.
Float and Shares Shorts:
At present, 95.93 million ATRA shares are outstanding with a float of 95.80 million shares on hand for trading. On Oct 30, 2023, short shares totaled 12.49 million, which was 12.25% higher than short shares on Sep 28, 2023. In addition to Dr. Pascal Touchon D.V.M. as the firm’s President, CEO & Director, Mr. K. Amar Murugan serves as its Executive VP & Chief Legal Officer.
Institutional Ownership:
Through their ownership of 107.64% of ATRA’s outstanding shares, institutional investors have majority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ATRA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ATRA analysts setting a high price target of $28.00 and a low target of $0.50, the average target price over the next 12 months is $8.12. Based on these targets, ATRA could surge 4900.0% to reach the target high and fall by -10.71% to reach the target low. Reaching the average price target will result in a growth of 1350.0% from current levels.
Summary of Insider Activity:
Insiders traded ATRA stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 11 while that of sell transactions has risen to 24 over the past year. The total number of shares bought during that period was 1,160,114 while 186,805 shares were sold.
